Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discussing CER Communications Asymmetry Is Putting The Cart Before The Horse – UPenn’s Caplan

Executive Summary

Current comparative research lacks firm quality data standards, including what would be considered accurate CER. Caplan notes that in today’s research environment, standards are determined by the peer review process and have no consistent application and no regulation. Before asymmetry can be addressed, these standards need to be determined.

You may also be interested in...

Additional Standards Needed To Make CER Meaningful And Adoptable, Case Study Shows

What started out as an exercise to show how comparative effectiveness research could be quickly adopted and help improve health outcomes ended up revealing that there remains a long way to go.

Industry’s CER Efforts Should Follow PCORI Methods, Cmte. Member Yancy Says

Pharma companies’ comparative effectiveness research should be “in sync” with nationalized approach that the Patient-Centered Outcomes Research Institute will bring, Clyde Yancy, member of the new institute’s Methodology Committee, suggests.

CER Credibility Lies In Methodology For Studies, Physician Tells BIO

The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts